Viatris (VTRS) Net Income towards Common Stockholders (2019 - 2026)
Viatris' (VTRS) quarterly Net Income towards Common Stockholders came in at $176.4 million in Q1 2026, up 105.8% year-on-year from $85.7 million in Q1 2025, and up 151.87% quarter-over-quarter from -$340.1 million in Q4 2025.
Viatris (VTRS) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
Viatris' Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at $176.4 million for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 105.8% year-over-year to $176.4 million in Q1 2026; TTM through Mar 2026 was -$296.5 million, a 92.18% increase from a year earlier, with the FY2025 full-year figure at -$3.5 billion, down 454.23% from the prior year.
- Net Income towards Common Stockholders grew to $176.4 million in Q1 2026 per VTRS's latest filing, from -$340.1 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $1.0 billion in Q4 2022 and bottomed at -$3.0 billion in Q1 2025.
- The 5-year median for Net Income towards Common Stockholders is $113.9 million (2024), against an average of -$108.2 million.
- Across the five-year window, Net Income towards Common Stockholders soared 483.32% in 2022 and slumped 2770.76% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at $1.0 billion in 2022, then slumped by 175.71% to -$765.6 million in 2023, then jumped by 32.54% to -$516.5 million in 2024, then jumped by 34.15% to -$340.1 million in 2025, then jumped by 151.87% to $176.4 million in 2026.
- Per Business Quant, the three latest VTRS Net Income towards Common Stockholders figures stand at $176.4 million (Q1 2026), -$340.1 million (Q4 2025), and -$128.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | -22.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 176.40 Mn |
| Dec 31, 2025 | -340.10 Mn |
| Sep 30, 2025 | -128.20 Mn |
| Jun 30, 2025 | -4.60 Mn |
| Mar 31, 2025 | -3.04 Bn |
| Dec 31, 2024 | -516.50 Mn |
| Sep 30, 2024 | 94.80 Mn |
| Jun 30, 2024 | -326.40 Mn |
| Mar 31, 2024 | 113.90 Mn |
| Dec 31, 2023 | -765.60 Mn |
| Sep 30, 2023 | 331.60 Mn |
| Jun 30, 2023 | 264.00 Mn |
| Mar 31, 2023 | 224.70 Mn |
| Dec 31, 2022 | 1.01 Bn |
| Sep 30, 2022 | 354.30 Mn |
| Jun 30, 2022 | 313.90 Mn |
| Mar 31, 2022 | 399.20 Mn |
| Dec 31, 2021 | -263.80 Mn |
| Sep 30, 2021 | 311.50 Mn |
| Jun 30, 2021 | -279.20 Mn |